ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploring Learning and Unlearning of Fear

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01512316
Recruitment Status : Unknown
Verified December 2011 by Universitaire Ziekenhuizen Leuven.
Recruitment status was:  Not yet recruiting
First Posted : January 19, 2012
Last Update Posted : January 19, 2012
Sponsor:
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

December 22, 2011
January 19, 2012
January 19, 2012
Not Provided
Not Provided
change in BOLD-signal during a fear conditioning task [ Time Frame: t0, t+24, t+48 ]
Subjects will participate in a 3-day experiment. Day1 (t0): Acquisition Day2 (T+24): extinction Day3 (T+48): re-exposure
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Exploring Learning and Unlearning of Fear
The Effect of D-cycloserine on Fear Learning and Extinction

The present study investigates the effect of d-cycloserine on learning and unlearning of fear in healthy humans and its underlying effect on the amygdala.

As a second objective, the effect of genotype on fear learning will be studied.

A growing body of evidence suggests that the extinction of fear is mediated by the N-methyl-D-aspartate (NMDA) receptor activity in the basolateral amygdala. Intra-amygdala infusions of antagonists of this glutamate receptor in small animals (eg: rats, mice) have demonstrated a blockage of fear acquisition and extinction. Agonists, on the other hand, facilitate conditioned fear extinction.

The animal studies are all based on the simple fear learning paradigm of conditioning. However, it is not clear that human anxiety disorders are based on prior conditioning encounter. Therefore it is important to disentangle the effect of DCS on acquisition and extinction in the context of a simple learning paradigm, particular its effect on the human amygdala.

Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Healthy Individuals
  • Drug: d-Cycloserine
    250mg, one dose, 2hrs prior to fMRI
    Other Name: Cycloserine, King Pharmaceuticals Ltd
  • Drug: Lactose pill
    one dose, 2hrs prior to fmri
  • Genetic: Saliva sample
    Buccal cell material will be sampled from all participants on day3
    Other Name: Whatman's Sterile Omni Swabs (www.whatman.com)
  • Other: Functional neuroimaging (fMRI)
  • Active Comparator: d-Cycloserine Acquisition
    d-Cycloserine will be given on day1, before acquisition
    Interventions:
    • Drug: d-Cycloserine
    • Genetic: Saliva sample
    • Other: Functional neuroimaging (fMRI)
  • Active Comparator: d-Cycloserine Extinction
    d-Cycloserine will be administered on day2, before extinction
    Interventions:
    • Drug: d-Cycloserine
    • Genetic: Saliva sample
    • Other: Functional neuroimaging (fMRI)
  • Placebo Comparator: Placebo
    A placebo pill will be administered on day1 and 2
    Interventions:
    • Drug: Lactose pill
    • Genetic: Saliva sample
    • Other: Functional neuroimaging (fMRI)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
90
Same as current
Not Provided
Not Provided

Inclusion Criteria:

  • No axis I diagnosis compatible with the DSM-IV by means of a structured diagnostic interview
  • Right-handed

Exclusion Criteria:

  • Current psychopharmacological or psychological treatment.
  • The presence of a physical/medical condition that may interfere with the study.
  • A contraindication for the use of DCS
  • Pacemaker, medication pump (such as insulin pump), hearing aid, removable prosthodontics
  • Metal in or on body (such as acupuncture needles, artificial limbs, stents, metal splints, clips, implanted electrodes, tattoos, or piercings)
Sexes Eligible for Study: All
18 Years to 40 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT01512316
IMDCSACQEXT
No
Not Provided
Not Provided
Universitaire Ziekenhuizen Leuven
Universitaire Ziekenhuizen Leuven
Not Provided
Not Provided
Universitaire Ziekenhuizen Leuven
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP